Detalles de la búsqueda
1.
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management.
Diabetes Obes Metab;
26(5): 1567-1581, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38328853
2.
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
Diabetes Obes Metab;
2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38618987
3.
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK.
Diabetes Obes Metab;
25(1): 132-143, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056765
4.
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Diabetes Obes Metab;
25(7): 1890-1899, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906837
5.
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Diabetes Obes Metab;
25(1): 46-55, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36111434
6.
Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.
Am Heart J;
243: 232-239, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34666013
7.
Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Cardiovasc Diabetol;
20(1): 139, 2021 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243779
8.
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Cardiovasc Diabetol;
20(1): 159, 2021 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34332558
9.
Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Diabetes Obes Metab;
23(2): 455-466, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33118320
10.
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study.
Diabetes Obes Metab;
23(6): 1431-1435, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33606906
11.
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Diabetes Obes Metab;
23(8): 1956-1960, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33852196
12.
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
Diabetes Obes Metab;
23(1): 39-48, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32845558
13.
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Cardiovasc Diabetol;
19(1): 196, 2020 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222693
14.
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
Diabetes Obes Metab;
22(9): 1481-1495, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32285611
15.
Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study.
Diabetes Obes Metab;
22(5): 828-837, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31944528
16.
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
Diabetes Obes Metab;
22(12): 2364-2374, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744392
17.
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Diabetes Obes Metab;
22(1): 66-78, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31468637
18.
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Diabetes Obes Metab;
21(11): 2474-2485, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297947
19.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Circulation;
136(3): 249-259, 2017 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28522450
20.
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
BMC Med;
16(1): 116, 2018 07 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30008267